吡哆醇预防妇科腹腔镜术后恶心呕吐:双盲随机对照试验
本研究为单中心双盲随机对照试验,纳入240例18至65岁择期全麻妇科腹腔镜手术患者,比较麻醉诱导前静脉给予维生素B6 0.2g与生理盐水对术后恶心呕吐的影响;两组均于诱导后给予地塞米松、术毕前给予昂丹司琼。吡哆醇组术后恶心呕吐发生率显著低于对照组(16.7% vs 35.8%),术后恶心发生率亦显著降低,但术后呕吐、首次恶心呕吐时间、疼痛及炎症指标无显著差异。
要点
- 妇科腹腔镜全麻患者诱导前给予维生素B6 0.2g可降低术后恶心呕吐发生率。
- 吡哆醇组术后恶心呕吐发生率为16.7%,对照组为35.8%,相对风险0.47。
- 术后呕吐、首次恶心呕吐时间、疼痛及IL-6、P物质无显著差异。
核心结论
- 在单中心随机试验中,吡哆醇联合地塞米松和昂丹司琼可降低择期全麻妇科腹腔镜手术患者术后恶心呕吐的发生率。
研究设计与样本
- 单中心双盲随机对照试验,筛查442例,最终240例18至65岁择期全麻妇科腹腔镜手术患者等量随机分为吡哆醇组和对照组。
- 吡哆醇组麻醉诱导前静脉给予维生素B6 0.2g,对照组给予生理盐水;两组均采用静吸复合全麻,诱导后给予地塞米松,术毕前给予昂丹司琼。
主要发现
- 术后恶心呕吐发生率吡哆醇组16.7%(20/120)显著低于对照组35.8%(43/120),相对风险0.47(95%CI 0.29至0.74),绝对风险降低0.20(95%CI 0.08至0.30),P=0.001。
- 术后恶心发生率吡哆醇组12.5%(15/120)显著低于对照组35%(42/120),相对风险0.36(95%CI 0.21至0.61),绝对风险降低0.23(95%CI 0.12至0.33),P<0.001。
- 术后呕吐、首次术后恶心呕吐发生时间、疼痛、血清白细胞介素-6和P物质、白细胞及中性粒细胞计数组间无统计学差异。
临床怎么用
- 对于择期全麻妇科腹腔镜手术患者,可考虑麻醉诱导前静脉给予维生素B6 0.2g以降低术后恶心呕吐发生率。
- 该干预需与地塞米松和昂丹司琼联合使用,证据来自单中心试验,需多中心多样本人群验证。
局限性
- 单中心研究,结果需多中心多样本人群验证以确保普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative nausea and vomiting are common complications after gynecologic laparoscopic surgery. Pyridoxine has been recommended as a first-line drug to prevent and treat nausea and vomiting during pregnancy; however, its efficacy in preventing postoperative nausea and vomiting remains unclear. METHODS: Patients of 18 to 65 yr old who received elective gynecologic laparoscopic surgery under general anesthesia were randomized into either the pyridoxine group or the control group. The pyridoxine group received 0.2 g of vitamin B 6 before anesthesia induction, and the control group received normal saline intravenously. Both groups received a similar regimen of combined intravenous and inhalation general anesthesia. All patients received dexamethasone (intravenous) after anesthesia induction and ondansetron (intravenous) before surgery completion. Postoperative nausea and vomiting occurrence was recorded according to the patients' self-reported data. Other clinical data were collected from hospital system, and concentrations of blood interleukin-6 and substance P were measured by enzyme-linked immunosorbent assay. RESULTS: A total of 442 patients were screened, and 240 patients were equally randomized to the pyridoxine or control group. The incidence of postoperative nausea and vomiting was statistically significant lower in the pyridoxine group than in the control group (16.7% [20 of 120] vs . 35.8% [43 of 120]; relative risk = 0.47 [95% CI, 0.29 to 0.74]; absolute risk reduction = 0.20 [95% CI, 0.08 to 0.30]; P = 0.001), and pyridoxine decreased the incidence of postoperative nausea (12.5% [15 of 120] vs . 35% [42 of 120]; relative risk = 0.36 [95% CI, 0.21 to 0.61]; absolute risk reduction = 0.23 [95% CI, 0.12 to 0.33]; P < 0.001). There were no statistical differences in postoperative vomiting, time to the first postoperative nausea and vomiting occurrence, pain, serum interleukin-6 and substance P, and leukocyte and neutrophil counts. CONCLUSIONS: In this single-center randomized trial, pyridoxine plus dexamethasone and ondansetron reduced the incidence of postoperative nausea and vomiting in patients undergoing elective gynecologic laparoscopic surgery under general anesthesia. These findings need to be validated in multicenter studies in diverse populations to ensure generalizability.
引用
- Zhang Q, Ye X, Shi S, et al. Pyridoxine Prevents Postoperative Nausea and Vomiting in Gynecologic Laparoscopic Surgery: A Double-blind Randomized Controlled Trial. Anesthesiology. 2024. PMID: 39729294. doi:10.1097/ALN.0000000000005354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。